“We are proud of our association with Tullis. They are a recognized leader in the health care investment community, in addition to being an invaluable resource to me.”
TO | Tullis Opportunity
Tullis Opportunity funds were first launched in 2008 to address the unusual market paradox of the time. Even against the backdrop of the global economic crisis and trying times for many traditional venture capital and private equity investors, there remained many attractive investment opportunities in health care, where returns could be achieved in a more timely manner. In the context of these funds, the term “Opportunity” refers to a quicker investment period and shorter fund life. Tullis currently manages two Tullis Opportunity funds that are comprised primarily of growth capital investments.
EXAMPLES: Tullis Opportunity Investments
Sirion Therapeutics was a pharmaceutical company that developed a number of innovative opthalmic products that addressed unmet medical needs in the protection and preservation of eyesight. The lead products of Sirion were acquired in 2009 in separate transactions by Alcon and Bausch & Lomb.
Vidacare is a leading developer, manufacturer and marketer of advanced intraosseous access technology for multiple diagnostic, monitoring and therapeutic applications. The EZ-IO® Intraosseous Infusion System is designed to provide immediate vascular access for dentists who may not be comfortable running an IV line in an emergency. Vidacare products are marketed in over 50 countries worldwide. Vidacare was acquired by Teleflex in a transaction providing approximately a 5X multiple to Tullis opportunity Fund.